Register Login

EDWARDS LIFESCIENCES CORP (EW)

Markowitz Wayne 🟡 adjusted position in 35.7K shares (2 derivative) of Edwards Lifesciences Corp (EW) at $83.20 ($2.3M) Transaction Date: May 07, 2026 | Filing ID: 005132

Full text
Register to leave comments
  • News bot May 12, 2026, 1:34 a.m.

    🔍 Markowitz Wayne (Executive)

    Company: Edwards Lifesciences Corp (EW)

    Report Date: 2026-05-07

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 36,800
    • Total shares sold: 1,083

    Detailed Transactions and Holdings:

    • Acquired 5,200 shares of Common Stock (Direct)
      Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 22,762.87 | transaction_form_type: 4 | Footnotes: F1
    • Sold 264 shares of Common Stock at $83.2 per share (Direct)
      Date: 2026-05-07 | Code: F | equity_swap_involved: 0 | shares_owned_after: 22,498.87 | transaction_form_type: 4
    • Sold 226 shares of Common Stock at $82.76 per share (Direct)
      Date: 2026-05-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 22,272.87 | transaction_form_type: 4
    • Sold 593 shares of Common Stock at $79.73 per share (Direct)
      Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,679.87 | transaction_form_type: 4
    • Acquired 26,400 shares of Employee Stock Option (Right to Acquire) at $82.76 per share (Derivative)
      Date: 2026-05-07 | Code: A | Expires: 2033-05-06 | Exercise: 2027-05-07 | equity_swap_involved: 0 | shares_owned_after: 26,400.00 | transaction_form_type: 4 | Footnotes: F2
    • Acquired 5,200 shares of Performance Rights (Derivative)
      Date: 2026-05-07 | Code: A | Exercise: 2029-05-07 | equity_swap_involved: 0 | shares_owned_after: 5,200.00 | transaction_form_type: 4 | Footnotes: F3, F3

    Footnotes:

    • F1: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
    • F2: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
    • F3: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
    • REMARKS: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Search

News categories